Amgen Inc. Share Price & Technical Analysis

AMGN · $337.4 (+1.76%)

Healthcare / Drug Manufacturers - General

AI Score 50 · Weak

$337.4

+1.76%

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wit

Price chart

Seasonality

May has 4 positive and 1 negative years (last 5 years shown)

1% return in May, 1% avg return in past 3 year May month.

8% return in 2026, 11% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
264%14%-9%-2%1%8%
259%7%1%-6%0%-2%5%-3%-2%5%16%-5%26%
249%-13%3%-3%12%2%6%-1%-3%-1%-11%-8%-7%
23-3%-7%5%-1%-8%1%6%9%4%-4%5%7%13%
222%0%7%-4%10%-6%2%-3%-7%18%6%-9%17%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 50/100

Weak · Emerging · Uptrend

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$181.49B

P/E ratio

23.39

52W high

$391.3

52W low

$267.8

Volume

18,60,408

Beta

0.43

Related stocks in Healthcare

Frequently asked questions

What is Amgen Inc. share price today?
Amgen Inc. (AMGN) last traded around $337.4 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does AMGN have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AMGN. Download the app for real-time alerts.
How can I analyze Amgen Inc. stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro